MyStart Health vs Wisp
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
MyStart Health
Best for fastest compounded GLP-1 onboarding with a price lockStarting at $299/mo
Wisp
Best for buyers who want a board-certified telehealth platform offering both branded injectables AND a sublingual alternative — with full disclosure that the sublingual form is not human-testedStarting at $225/mo
Side-by-Side Comparison
| Feature | MyStart Health | Wisp |
|---|---|---|
| Overall Score | ✓7.7/10 | 7.0/10 |
| Starting Price | $299/mo | ✓$225/mo |
| Editorial Rating | ✓3.9 ★ /5 | 3.5 ★ /5 |
| Features | 6 features | 6 features |
| States Available | 0 | 0 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | — | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
MyStart Health
Pros
- ✓Price Lock Guarantee — base monthly rate ($299) doesn't increase even when your prescribed dose escalates
- ✓Fast onboarding: quoted 5-minute intake, 24-hour prescription turnaround, 2–4 day shipping
- ✓24/7 access to the care team with unlimited clinician messaging included
- ✓LegitScript certified
- ✓Transparent Section 503A compounding disclosure on every landing page
Cons
- ✗Not BBB accredited — BBB rating of C+ with 10 complaints filed against the business (BBB file opened April 24, 2025), most involving shipping delays and customer service access issues in early 2026
- ✗Compounded only — no FDA-approved Ozempic, Wegovy, Zepbound, or Mounjaro
- ✗Oral tirzepatide referenced in marketing but FAQ clarifies injectable is 'currently more common' — no FDA-approved oral tirzepatide exists, and the November 2025 Chimicles class action against OpenLoop/Triad Rx over unapproved oral tirzepatide products is a cautionary data point for the category
- ✗Very recent company (incorporated May 21, 2024 per BBB) — limited operational track record
- ✗Pharmacy partners not publicly named — no independent way to verify 503A compliance
- ✗Clinical efficacy claims are based on a homepage survey of only 16 self-reporting customers
Wisp
Pros
- ✓Wider GLP-1 menu than the prior stub suggested — both branded injectables (Wegovy, Zepbound, Saxenda) AND the compounded sublingual option
- ✓LegitScript certified, board-certified providers (Dr. Shannon Chatham DO, Andrea Sleeth WHNP-BC publicly named)
- ✓Wisp's product page uses appropriately cautious language around sublingual: 'lab tests using human-derived tissues suggest it may begin working' and 'effectiveness in patients may vary' — disclosure is more rigorous than most compounded GLP-1 marketing
Cons
- ✗EFFECTIVENESS CAVEAT: sublingual compounded semaglutide has not been tested in humans — Wisp's own product page explicitly states this. Injectables (Wegovy, Zepbound, Saxenda) on the same platform have FDA safety/efficacy data; sublingual does not.
- ✗Pharmacy partners not publicly named
- ✗States served list not publicly enumerated
Our Verdict
MyStart Health edges out Wisp with a higher overall score of 7.7/10 and is particularly strong for fastest compounded GLP-1 onboarding with a price lock. Wisp remains a solid alternative, especially if you're looking for buyers who want a board-certified telehealth platform offering both branded injectables AND a sublingual alternative — with full disclosure that the sublingual form is not human-tested.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.